ANAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Preferred stock is a special equity security that has properties of both equity and debt. Anacor Pharmaceuticals's preferred stock for the quarter that ended in Mar. 2016 was $0.00 Mil.
The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Anacor Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 was $2,351.35 Mil.
In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Anacor Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2016 was $0.98.
Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Anacor Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2016 was $-0.36.
The historical data trend for Anacor Pharmaceuticals's Preferred Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anacor Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Preferred Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Anacor Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | |
Preferred Stock | Get a 7-Day Free Trial | - | - | - | - | - |
Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.
Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.
Preferred stock comes in many forms. It can be:
A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.
Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?
It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.
Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.
Anacor Pharmaceuticals (NAS:ANAC) Preferred Stock Explanation
When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.
For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffetts Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffetts Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?
1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.
Anacor Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 is calculated as
Enterprise Value | |||||||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation | + | Minority Interest |
= | 2424.860805 | + | 0 | + | 62.255 | + | 0 | + | 0 |
- | Cash, Cash Equivalents, Marketable Securities | ||||||||
- | 135.766 | ||||||||
= | 2,351.35 |
2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.
Anacor Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2016 is calculated as
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (Diluted Average) |
= | (44.584 | - | 0) | / | 45.3669 | |
= | 0.98 |
3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.
Anacor Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2016 is calculated as
Earnings per Share (Diluted) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-16.147 | - | 0) | / | 44.872 | |
= | -0.36 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Anacor Pharmaceuticals's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith R Leonard | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
William Jl Rieflin | director | NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anders D Hove | director | 30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112 |
Lucy Shapiro | director | 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121 |
Graeme Bell | officer: Executive VP and CFO | 1324 WAVERLY ROAD, GLADWYNE PA 19035 |
Ryan T Sullivan | officer: EVP and General Counsel | C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855 |
Wendall Wierenga | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Paul L Berns | director, officer: President and CEO | 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
Mark Leschly | director | RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019 |
Geoffrey M. Parker | officer: Executive Vice President & CFO | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Paul H Klingenstein | director | 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
David P Perry | director, officer: President and CEO | 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Rho Management Ventures Iv Llc | 10 percent owner | 124 DUNE RD, QUOGUE NY 11959 |
Rho Ventures Iv Qp Lp | 10 percent owner | 124 DUNE RD, QUOGUE NY 11959 |
Rho Ventures Iv Lp | 10 percent owner | 124 DUNE ROAD, QUOGUE NY 11959 |
From GuruFocus
By Business Wire Business Wire • 02-10-2023
By Business Wire Business Wire • 06-02-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.